Cover Image

The influence of alternative medicine in highly active antiretroviral treatment

Fuente: Redalyc

Saved in:

Bibliographic Details
Main Author:	M. Vázquez Hernández
Format:	Artículo científico
Language:	en
Published:	Sociedad Española de Farmacia Hospitalaria 2009
Subjects:	Medicina HIV HAART Medicinal plants Drug interactions
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glomerulopatías halladas en pacientes HIV (+) casuística de un Hospital Público de la Ciudad de Buenos Aires.
by: José Petrolito
Published: (2009)

Infecções oportunistas em indivíduos com infecção pelo HIV e relação com uso de terapia antirretroviral
by: Vinicius Henrique Veraldo Fagundes
Published: (2010)

Origin and Evolutionary History of HIV-1 Subtype B in Cuba
by: Liuber Y. Machado-Zaldívar
Published: (2017)

Approach to establishing and evaluating clinical relevance of drugs interactions in HIV patients: 2009 update
by: N.A. Giraldo
Published: (2010)

Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population
by: Carla Bastida
Published: (2017)

Potential interactions in a cohort of elderly HIV-positive patients
by: Lorena Jiménez-Guerrero
Published: (2018)

Sarcoma de Kaposi diseminado asociado al uso de corticosteroides en paciente con SIDA
by: Martha Rodríguez
Published: (2014)

Tendencia de la tuberculosis en cohortes de pacientes VIH positivos antes y después de la era HAART en instituciones de salud de Medellín (1996-2005)
by: Alexánder Arbeláez
Published: (2007)

Potential drug interactions in relation with the use, medicine plants and herbal in premenopausal women period
by: Gabriela Tassotti Gelatti
Published: (2016)

Manifestaciones Clínicas y Evaluación Diagnóstica en el Sarcoma de Kaposi
by: Rocío Paola Cardozo
Published: (2010)

Perspectives of people with HIV and HIV clinicians on characteristics of antiretroviral treatment and HIV‐related symptoms
by: M. José Galindo Puerto, et al.
Published: (2024)

Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda
by: Tom G. Jacobs, et al.
Published: (2024)

Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment
by: D. Dulana C. Suriyarachchi, et al.
Published: (2025)

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia
by: Ekaterina Ozhmegova, et al.
Published: (2024)

Effectiveness of switching regimen in people living with HIV and persistent low‐level viraemia in the modern antiretroviral treatment era
by: Tommaso Clemente, et al.
Published: (2026)

Individual characteristics and time‐updated factors associated with antiretroviral treatment interruptions among people living with HIV in British Columbia, Canada
by: Jermia Foncham, et al.
Published: (2026)

Long‐term immune reconstitution patterns and influencing factors in people living with HIV exhibiting suboptimal immune response after 24 months of antiretroviral therapy
by: Liting Yan, et al.
Published: (2026)

The silent crisis: Vertical HIV transmission and the struggle for antiretroviral access
by: Pérez‐Cavazos Samantha, et al.
Published: (2025)

Molecular epidemiological analysis and investigation of antiretroviral drug resistance profile, including capsid inhibitors, among treatment‐naïve individuals with HIV ‐1 in Türkiye
by: Adem Özdemir, et al.
Published: (2025)

The role of an artificial intelligence model in antiretroviral therapy counselling and advice for people living with HIV
by: Matthew Chung Yi Koh, et al.
Published: (2024)

Transitions in treatment: A systematic review and meta‐aggregation of preferences and barriers in switching from oral to long‐acting injectable antiretroviral therapy among people living with HIV and stakeholders
by: Tiantian Hu, et al.
Published: (2025)

Hepatitis B reactivation in people living with HIV and isolated anti‐ HBc receiving tenofovir‐sparing dual antiretroviral therapy
by: M. D. M. Arcos‐Rueda, et al.
Published: (2026)

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy
by: Tali Faggiano, et al.
Published: (2025)

Dual drivers of polypharmacy in people with HIV : Quantifying the independent associations of aging and long‐term antiretroviral therapy
by: Shigeru Hasebe, et al.
Published: (2025)

Current characteristics of tuberculosis and human immunodeficiency virus co-infection in a cohort of hospitalized patients in Medellín, Colombia
by: Lina Ruiz
Published: (2018)

Diabetes risk in HIV infection and antiretroviral therapy: A systematic review and meta‐analysis of prospective cohort evidence
by: Xuanlan Li, et al.
Published: (2026)

Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy
by: Vincenzo Malagnino, et al.
Published: (2024)

Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?
by: Arda Kaya, et al.
Published: (2025)

Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States : Findings from the antiretroviral pregnancy registry
by: William R. Short, et al.
Published: (2025)

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV : A systematic review and meta‐analysis
by: Melani Ratih Mahanani, et al.
Published: (2026)

Retention outcomes during same‐day antiretroviral therapy initiation in health facilities and outreach settings of Rakai, Uganda, 2016–2021
by: Jesca Basiima, et al.
Published: (2025)

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide ( B/F/TAF ) in people previously treated with darunavir‐based antiretroviral therapy
by: Rhianna Sheridan, et al.
Published: (2026)

De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study
by: P. Oosterhof, et al.
Published: (2024)

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls
by: S. Savinelli, et al.
Published: (2025)

Modelo unibimodal simétrico-asimétrico con aplicación al estudio del RNA VIH-1
by: Guillermo Martínez-Flórez
Published: (2014)

Immune non‐response despite effective antiretroviral therapy in people living with HIV : A review of potential mechanisms, biomarkers and therapeutic approaches
by: Charlotte Silvestre, et al.
Published: (2026)

No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people withHIV with profound immunosuppression
by: Chi Kuen Chan, et al.
Published: (2024)

AI in medicine: No longer the future, but the present
by: Abiu Sempere, et al.
Published: (2024)

Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4‐FHDH)
by: S. Abgrall, et al.
Published: (2024)

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study
by: C. Busca‐Arenzana, et al.
Published: (2024)